|
Name |
[4-Amino-2-(benzylamino)-1,3-thiazol-5-yl](4-fluorophenyl)methanone
|
| Molecular Formula | C17H14FN3OS | |
| IUPAC Name* |
[4-amino-2-(benzylamino)-1,3-thiazol-5-yl]-(4-fluorophenyl)methanone
|
|
| SMILES |
C1=CC=C(C=C1)CNC2=NC(=C(S2)C(=O)C3=CC=C(C=C3)F)N
|
|
| InChI |
InChI=1S/C17H14FN3OS/c18-13-8-6-12(7-9-13)14(22)15-16(19)21-17(23-15)20-10-11-4-2-1-3-5-11/h1-9H,10,19H2,(H,20,21)
|
|
| InChIKey |
JFBJKTYJJCAKHN-UHFFFAOYSA-N
|
|
| Synonyms |
[4-amino-2-(benzylamino)-1,3-thiazol-5-yl](4-fluorophenyl)methanone; ZINC4722374; STK781672; AKOS001754627; NCGC00318368-01; AB01311719-01; Methanone, [4-amino-2-[(phenylmethyl)amino]-5-thiazolyl](4-fluorophenyl)-
|
|
| CAS | NA | |
| PubChem CID | 5297493 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 327.4 | ALogp: | 4.7 |
| HBD: | 2 | HBA: | 6 |
| Rotatable Bonds: | 5 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 96.2 | Aromatic Rings: | 3 |
| Heavy Atoms: | 23 | QED Weighted: | 0.682 |
| Caco-2 Permeability: | -4.881 | MDCK Permeability: | 0.00002400 |
| Pgp-inhibitor: | 0.471 | Pgp-substrate: | 0.959 |
| Human Intestinal Absorption (HIA): | 0.005 | 20% Bioavailability (F20%): | 0.002 |
| 30% Bioavailability (F30%): | 0.013 |
| Blood-Brain-Barrier Penetration (BBB): | 0.853 | Plasma Protein Binding (PPB): | 96.89% |
| Volume Distribution (VD): | 0.784 | Fu: | 3.30% |
| CYP1A2-inhibitor: | 0.967 | CYP1A2-substrate: | 0.66 |
| CYP2C19-inhibitor: | 0.956 | CYP2C19-substrate: | 0.058 |
| CYP2C9-inhibitor: | 0.906 | CYP2C9-substrate: | 0.027 |
| CYP2D6-inhibitor: | 0.918 | CYP2D6-substrate: | 0.127 |
| CYP3A4-inhibitor: | 0.916 | CYP3A4-substrate: | 0.252 |
| Clearance (CL): | 7.571 | Half-life (T1/2): | 0.036 |
| hERG Blockers: | 0.039 | Human Hepatotoxicity (H-HT): | 0.949 |
| Drug-inuced Liver Injury (DILI): | 0.979 | AMES Toxicity: | 0.85 |
| Rat Oral Acute Toxicity: | 0.161 | Maximum Recommended Daily Dose: | 0.942 |
| Skin Sensitization: | 0.099 | Carcinogencity: | 0.744 |
| Eye Corrosion: | 0.003 | Eye Irritation: | 0.406 |
| Respiratory Toxicity: | 0.064 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC001400 | ![]() |
0.391 | D0X7GL | ![]() |
0.391 | ||
| ENC000209 | ![]() |
0.386 | D0YB1G | ![]() |
0.372 | ||
| ENC000302 | ![]() |
0.356 | D02IHW | ![]() |
0.352 | ||
| ENC000077 | ![]() |
0.345 | D0Y7EM | ![]() |
0.349 | ||
| ENC000093 | ![]() |
0.338 | D03CJL | ![]() |
0.349 | ||
| ENC001449 | ![]() |
0.330 | D06LHG | ![]() |
0.348 | ||
| ENC001352 | ![]() |
0.319 | D0G1VX | ![]() |
0.345 | ||
| ENC001291 | ![]() |
0.319 | D0J1MI | ![]() |
0.344 | ||
| ENC000908 | ![]() |
0.318 | D0H6TP | ![]() |
0.341 | ||
| ENC003516 | ![]() |
0.315 | D0X5UN | ![]() |
0.336 | ||